Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOP Ependymoma II overall program
2013-002766-39Phase 2Active
- Sponsor
- Centre Léon Bérard
- Start
- Dec 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of vincristine, etoposide, cyclophosphamide, cisplatin, carboplatin and 2 more in ependymoma, sponsored by Centre Léon Bérard. Primary endpoint: Gross Total Resection rate. Started Dec 2013; status: active.
02
Drugs
vincristineetoposidecyclophosphamidecisplatincarboplatin
03
Conditions
ependymoma
Beyond the preview
Go deeper on 2013-002766-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002766-39.